

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



AIM Vaccine Co., Ltd.
艾美疫苗股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 06660)

- (1) POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING
HELD ON JUNE 10, 2026;**
- (2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION;**
- (3) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND
APPOINTMENT OF DIRECTORS;**
- (4) APPOINTMENT OF EXECUTIVE PRESIDENT; AND**
- (5) CHANGE IN COMPOSITION OF BOARD COMMITTEES**

(1) POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING

The board of directors (the “**Board**”) of AIM Vaccine Co., Ltd. (the “**Company**”) is pleased to announce the poll results of the 2025 annual general meeting (the “**AGM**”) held at meeting room, 10/F, Gangwu Building, No. 1 Fenghe Road, Lujiazui Street, Pudong New District, Shanghai, the PRC at 10:00 a.m. on Wednesday, June 10, 2026.

References are made to (i) the notice of the AGM, (ii) the circular (the “**Circular**”) of the Company dated May 19, 2026. Unless otherwise defined, the terms used in this announcement shall have the same meanings as those defined in the Circular.

Attendance of the AGM

Shareholders (or their proxies) attending the AGM held 895,769,144 Shares with voting rights in aggregate, representing approximately 73.03% of the total issued Shares. To the best knowledge, information and belief of the Directors: (i) no Shareholder was required under the Listing Rules to abstain from voting on the resolutions proposed at the AGM; (ii) there was no Share entitling the holder thereto to attend the AGM and abstain from voting in favour of the resolutions proposed at the AGM under Rule 13.40 of the Listing Rules; and (iii) no Shareholders have indicated in the Circular that they intend to vote against or to abstain from voting on the resolutions proposed at the AGM.

Poll Results of the Resolutions Proposed at the AGM

The resolutions of the AGM were voted on by poll. The voting results of the resolutions proposed at the AGM are as follows:

ORDINARY RESOLUTIONS		Number of Votes (%)		
		For	Against	Abstain
1.	To consider and approve the report of the Directors for the year 2025.	895,769,144 (100.000%)	0 (0.000%)	0 (0.000%)
2.	To consider and approve the 2025 annual report of the Company.	895,769,144 (100.000%)	0 (0.000%)	0 (0.000%)
3.	To consider and approve the final settlement of accounts of the Company for the year 2025.	895,769,144 (100.000%)	0 (0.000%)	0 (0.000%)
4.	To consider and approve the audited financial statements of the Group for the year 2025.	895,769,144 (100.000%)	0 (0.000%)	0 (0.000%)
5.	To consider and approve the grant of authorization to the Board to approve the financial budget of the Group for the year 2026.	894,647,945 (99.875%)	1,121,199 (0.125%)	0 (0.000%)
6.	To consider and approve the profit distribution plan of the Company for the year 2025.	895,769,144 (100.000%)	0 (0.000%)	0 (0.000%)
7.	To consider and approve the re-appointment of Ernst & Young as auditor of the Company for the year 2026.	895,769,144 (100.000%)	0 (0.000%)	0 (0.000%)
8.	To consider and approve the appointment of the following Directors:			
a.	Ms. Ling LIU as an executive Director.	895,769,144 (100.000%)	0 (0.000%)	0 (0.000%)
b.	Mr. Hui OUYANG as an independent non-executive Director.	893,916,782 (100.000%)	0 (0.000%)	0 (0.000%)
c.	Mr. Weicai SHAO as an independent non-executive Director.	894,102,144 (100.000%)	0 (0.000%)	0 (0.000%)

SPECIAL RESOLUTIONS		Number of Votes (%)		
		For	Against	Abstain
9.	To consider and approve the resolution on the proposed amendments to the Articles of Association and the Rules of Procedure of the Board of Directors.	895,769,144 (100.000%)	0 (0.000%)	0 (0.000%)
10.	To grant the Board a general mandate to allot, issue or otherwise deal with new Shares not exceeding 20% of the total number of Shares in issue as at the date of passing the special resolution according to special resolution No. 10 set out in the Circular.	894,634,745 (99.873%)	1,134,399 (0.127%)	0 (0.000%)
11.	To grant the Board a general mandate to repurchase H Shares not exceeding 10% of the total number of H Shares in issue as at the date of passing the special resolution according to special resolution No. 11 set out in the Circular.	895,769,144 (100.000%)	0 (0.000%)	0 (0.000%)

Notes:

- (a) As more than one-half of the votes were cast in favour of the above resolutions No. 1 to No. 8 of the AGM, the above resolutions were duly passed as ordinary resolutions of the Company.
- (b) As more than two-thirds of the votes were cast in favour of the above resolutions No. 9 to No. 11 of the AGM, the above resolutions were duly passed as special resolutions of the Company.
- (c) As at the record date of the AGM, the total number of issued Shares of the Company was 1,226,562,599 Shares, which consisted of 507,673,711 H Shares and 718,888,888 Domestic Shares.
- (d) As at the record date of the AGM, the total number of Shares of the Company entitling the holders to attend and vote on the resolutions at the AGM was 1,226,562,599, which consisted of 507,673,711 H Shares and 718,888,888 Domestic Shares.
- (e) The convening of the AGM and the procedure for holding of the AGM were in compliance with the requirements of PRC laws, administrative regulations and the Articles of Association.
- (f) Tricor Investor Services Limited, the Company's H Share registrar, a representative from the audit committee of the Company and a Shareholder representative acted as the counters and scrutineers for the vote-taking at the AGM.
- (g) All Directors of the Board of the Company attended the AGM either in person or through video or teleconference.

(2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION

A special resolution was duly passed by the Shareholders at the AGM to approve the proposed amendments to the Articles of Association as set out in the Circular. Accordingly, the amended Articles of Association shall become effective from the date of the AGM. The full text of the amended Articles of Association will be published on the websites of the Company (www.aimbio.com) and the Stock Exchange (www.hkexnews.hk).

(3) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND APPOINTMENT OF DIRECTORS

The resolutions on the appointment of Ms. Ling LIU (“**Ms. LIU**”) as an executive Director and Mr. Hui OUYANG (“**Mr. OUYANG**”) and Mr. Weicai SHAO (“**Mr. SHAO**”) as independent non-executive Directors of the Company were duly passed by the Shareholders at the AGM and has taken effect from the conclusion of the AGM. The term of each of the aforementioned Directors will commence from the date of the AGM and ending on the expiry of the Second Session of the Board.

Reference is made to the announcement of the Company dated May 18, 2026. As the Articles of Association has been amended and the new independent non-executive Directors have been appointed, the resignation of Ms. Jie WEN from her position as an independent non-executive Director, a member of the audit committee of the Company, a member of the remuneration and appraisal committee of the Company and a member of the nomination committee of the Company has come into effect from June 10, 2026.

The biographical details of Ms. LIU, Mr. OUYANG and Mr. SHAO are set out below:

Ms. Ling LIU (劉靈), aged 43, has served in various management positions since she joined our Company in November 2011 and has served as the secretary to the Board since November 2015, chief investment officer since March 2022, one of the joint company secretaries from September 2022 to December 2025, the sole company secretary since December 2025, and vice president since April 2023. She is in charge of the general office of the Board and investment management of the Company. Her main responsibilities include such matters as information disclosure, investor relations, equity management and corporate governance of the Company.

Ms. LIU has been a director of Hong Kong AIM Vaccine Limited (艾美疫苗有限公司) since September 2025. She also served as the chairman of the board of directors of AIM Rongyu (Ningbo) Biopharmaceutical Co., Ltd. (艾美榮譽(寧波)生物製藥有限公司) from December 2019 to June 2021. She was a director of AIM Persistence Biopharmaceutical Co., Ltd. (艾美堅持生物製藥有限公司) from February 2014 to January 2019.

Ms. LIU received her Executive Master of Business Administration degree from W. P. Carey School of Business of Arizona State University in the U.S. in May 2018.

Mr. Hui OUYANG (歐陽輝), aged 63, was one of the independent non-executive Directors of the Company from May 2021 to April 2025. He is the Senior Vice Dean and Distinguished Dean's Chair Professor of Finance at the Cheung Kong Graduate School of Business (長江商學院) in the PRC, and serves as the Director of the Center for Financial Innovation and Wealth Management. He is also a Distinguished Professor at the China Capital Market Institute of the China Securities Regulatory Commission. He serves as an independent director and senior advisor to several companies, including being an independent non-executive director of Ping An Insurance (Group) Company of China, Ltd. (stock code: 2318.HK) from August 2017 to July 2023 and an independent director of Sleemon Healthy Sleep Technology Co., Ltd. (喜臨門健康睡眠科技股份有限公司) (stock code: 603008.SH) since July 2024.

Mr. OUYANG previously served as a managing director at Lehman Brothers Holdings Inc., Nomura Securities Co., Ltd., and UBS Group AG. He was responsible for asset allocation, credit derivative pricing, and alpha-beta structured products at major financial institutions, as well as providing solutions and product recommendations for investment and financing, cost management, and business development at large enterprises.

Mr. OUYANG was granted lifetime tenure at the University of North Carolina and served as an associate professor at Duke University. He was named the Best Professor for Duke University's 2004 Global Executive EMBA class. He independently received the prestigious 2003 Michael Brennan Award from the Review of Financial Studies and shared the 2005 Best Paper Award from the Society of Quantitative Analysts with Mr. Henry Cao.

Mr. OUYANG holds a Ph.D. in Finance from the University of California, Berkeley in the U.S., and a Ph.D. in Chemical Physics from Tulane University in the U.S. He also conducted postdoctoral research in Chemical Physics at the California Institute of Technology in the U.S. under the guidance of Nobel laureate Prof. Rudolph Arthur Marcus.

Mr. Weicai SHAO (邵偉才), aged 42, has over 15 years of experience in investment banking and auditing. He has previously served as a senior auditor at Ernst & Young Hua Ming LLP (安永華明會計師事務所(特殊普通合夥)) and as a business director at the Investment Banking Division of Guosen Securities Co., Ltd. (國信證券股份有限公司) (stock code: 002736.SZ). From April 2011 to April 2021, he worked at Huaxi Securities Co., Ltd. (華西證券股份有限公司) (stock code: 002926.SZ), serving successively as deputy general manager of the Investment Banking Division and general manager of the Shanghai Business Department. From May 2021 to April 2022, he served as the executive general manager of the Investment Banking Committee of CSC Financial Co., Ltd. (中信建投證券股份有限公司) (stock code: 601066.SH, 6066.HK). Since June

2022, he has served as the executive director of Shanghai Zhaoyang Zhicheng Enterprise Management Consulting Co., Ltd. (上海昭陽至誠企業管理諮詢有限公司). During his tenure in investment banking, he led and successfully completed initial public offering, follow-on financing, and mergers and acquisitions restructuring projects for numerous companies, including Sichuan Hebang Biotechnology Co., Ltd. (四川和邦生物科技股份有限公司) (stock code: 603077.SH) and Tibet AIM Pharm. Inc. (西藏易明西雅醫藥科技股份有限公司) (stock code: 002826.SZ).

Mr. SHAO holds a Master of Finance from Shanghai University of Finance and Economics (上海財經大學) in the PRC and a Bachelor of Finance from Shandong University (山東大學) in the PRC.

As at the date of this announcement, save as disclosed above, Ms. LIU, Mr. OUYANG and Mr. SHAO have confirmed that (i) they have no relationship with any Directors, senior management, substantial Shareholders or controlling Shareholders (as respectively defined in the Listing Rules) of the Company; (ii) they do not hold any other position with the Company or its subsidiaries; (iii) they did not hold any directorships in any other listed companies the securities of which are listed on any securities markets in Hong Kong or overseas in the last three years; (iv) they are not interested in nor are deemed to be interested in any shares or underlying shares of the Company or its associated corporations within the meaning of Part XV of the SFO and (v) they have no other matters relating to their elections that need to be brought to the attention of the Shareholders or the Stock Exchange or to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules. Their remuneration will be disclosed in the next annual report of the Company.

Mr. OUYANG and Mr. SHAO have confirmed (i) their independence in accordance with Rule 3.13 of the Listing Rules; (ii) that they have no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as is defined in the Listing Rules) of the Company; and (iii) that there are no other factors that may affect their independence at the time of their elections as independent non-executive Directors of the Second Session of the Board. The Board and the Nomination Committee are also of the view that Mr. OUYANG and Mr. SHAO meet the independence guidelines set out under Rule 3.13 of the Listing Rules and consider both of them to be independent of the Company.

(4) APPOINTMENT OF EXECUTIVE PRESIDENT

The Board is pleased to announce that Mr. Jinan WU (“**Mr. WU**”) has been appointed as the executive president, the chief scientist, and the chairman of the research and development management committee of the Company and shall be responsible for research and development and related work of the Company. The term of Mr. WU commences from June 10, 2026 and terminates upon the expiry of the second session of the Board.

The biographical details of Mr. WU are set out below:

Mr. Jinan WU (吳季南), aged 57, has over 15 years of experience in the research and development of the biomedical field. From 1991 to 2002, he worked successively in the Epidemiology Department and Quality Assurance Department of Wuhan Institute of Biological Products (武漢生物製品研究所流行病室、質量保證處). From 2005 to 2012, he worked in the Hepatitis B Gene Laboratory, Rabies Vaccine Laboratory, and R&D Department of Wuhan Institute of Biological Products (武漢生物製品研究所基因乙肝室、狂苗室及研發部), successively serving as the Director of the Hepatitis B Gene Laboratory, the Director of the Rabies Vaccine Laboratory, and the Project Leader of the 973 Research Project.

Mr. WU has worked at AIM Rongyu (Ningbo) Biopharmaceutical Co., Ltd. (艾美榮譽(寧波)生物製藥有限公司) since 2013, successively serving as its head of the R&D Department and its general manager.

As at the date of this announcement, save as disclosed above, Mr. WU has confirmed that (i) he has no relationship with any Directors, senior management, substantial Shareholders or controlling Shareholders (as respectively defined in the Listing Rules) of the Company; (ii) he does not hold any other position with the Company or its subsidiaries; (iii) he did not hold any directorships in any other listed companies the securities of which are listed on any securities markets in Hong Kong or overseas in the last three years; (iv) he is not interested in nor are deemed to be interested in any shares or underlying shares of the Company or its associated corporations within the meaning of Part XV of the SFO and (v) he has no other matters relating to his election that need to be brought to the attention of the Shareholders or the Stock Exchange or to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

(5) CHANGE IN COMPOSITION OF BOARD COMMITTEES

Reference is made to the announcement of the Company dated May 18, 2026 in relation to the resignation of Ms. Jie WEN, an independent non-executive Director of the Company and the proposed election of Directors. Following the conclusion of the AGM regarding the amendments to the Articles of Association concerning the number of Directors and the appointment of Directors, the Board hereby announces that, the composition of the following Board committees of the Company has been changed as follows with effect from June 10, 2026 and terminates upon the expiry of the second session of the Board:

The composition of the Audit Committee is changed to: Professor Ker Wei PEI (Chairman), Mr. Xiaoguang GUO and Mr. Weicai SHAO.

The composition of the Remuneration and Appraisal Committee is changed to: Mr. Weicai SHAO (Chairman), Mr. Wen GUAN and Mr. Xiaoguang GUO.

The composition of the Nomination Committee is changed to: Mr. Xiaoguang GUO (Chairman), Ms. Ling LIU and Mr. Hui OUYANG.

The composition of the Strategy Committee is changed to: Mr. Hui OUYANG (Chairman), Mr. Yan ZHOU, Mr. Xin ZHOU, Mr. Shaojun JIA and Mr. Wen GUAN.

The composition of the Compliance and Risk Control Committee is changed to: Mr. Yan ZHOU (Chairman), Mr. Jie ZHOU and Mr. Jichen ZHAO.

By order of the Board
AIM Vaccine Co., Ltd.
Chairman of the Board and CEO
Mr. Yan ZHOU

Beijing, the PRC, June 10, 2026

As at the date of this announcement, the Board comprises Mr. Yan ZHOU, Mr. Xin ZHOU, Mr. Shaojun JIA, Mr. Wen GUAN, Mr. Jie ZHOU and Ms. Ling LIU as executive directors; Mr. Jichen ZHAO as a non-executive director; and Professor Ker Wei PEI, Mr. Xiaoguang GUO, Mr. Hui OUYANG and Mr. Weicai SHAO as independent non-executive directors.